NCT03953599View on ClinicalTrials.gov

CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 1, 2019

Primary Completion Date

July 1, 2021

Study Completion Date

December 31, 2021

Conditions
B Cell Malignancy
Interventions
BIOLOGICAL

CD19-STAR-T cells

CD19-STAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of STAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest for 2 days before infusion.

Trial Locations (1)

065200

Hebei Yanda Ludaopei Hospital, Sanhe

All Listed Sponsors
collaborator

China Immunotech (Beijing) Biotechnology Co., Ltd.

INDUSTRY

lead

Hebei Yanda Ludaopei Hospital

OTHER

NCT03953599 - CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients | Biotech Hunter | Biotech Hunter